Liu Guolong
PhD in Oncology- Chief Physician
- Professor
- Postdoctoral Co-Supervisor
Specialty: Medical Oncology
Languages: English · Mandarin
Conditions Treated
- Nasopharyngeal Carcinoma
- Lung Cancer
- Liver Cancer
- Colorectal Cancer
- Esophageal Cancer
- Solid Tumors
Procedures
- Chemotherapy
- Chemoradiotherapy
- Targeted Therapy
- Immunotherapy
- Multimodal Cancer Treatment
- Sphincter-Preserving Treatment for Colorectal Cancer
Expertise
Professor Guolong Liu is a medical oncologist with more than 35 years of experience in the multidisciplinary treatment of solid tumors. His clinical strengths include combined chemoradiotherapy for nasopharyngeal carcinoma, early detection and systemic treatment of lung and liver cancers, and sphincter-preserving treatment strategies for colorectal cancer. He integrates chemotherapy, targeted therapy, immunotherapy, radiotherapy and local treatment according to tumor type and disease stage. This broad multimodal perspective is particularly valuable for patients who require individualized sequencing of several treatment approaches.
Experience
- Chair, Radiation Therapy Society, Guangzhou Medical Association
- Vice President, Guangzhou Anti-Cancer Association
- Chair, Specialty Committee of Hyperthermia and Ablation Therapy
- Standing Committee Member, Oncology Society of Guangdong Medical Association
Research & Publications
- NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy Clinical & Translational Oncology, 2025.
- Circulating tumor cells as a new predictive and prognostic factor in patients with small cell lung cancer Journal of Cancer, 2020.
- MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway BMC Cancer, 2019.
- The Impact of Clinical Stage on Radiation Doses to Organs at Risk Following Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma Journal of Cancer, 2016.
- IL-17A promotes migration and tumor killing capability of B cells in esophageal squamous cell carcinoma Oncotarget, 2016.
- miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen International Journal of Clinical and Experimental Medicine, 2014.
Locations
Shenzhen Qianhai Taikang Hospital
No. 3099 Menghai Avenue, Nanshan District, Shenzhen, Guangdong 518052, China Get directions